MediLink Therapeutics (Suzhou) Co Ltd, a China-based clinical-stage biotech company, announced on Monday that it has entered into a global clinical trial collaboration and supply agreement with US biopharmaceutical company Amgen Inc (NASDAQ:AMGN).
Under the agreement, Amgen will lead a global clinical study to assess the therapeutic potential of the combination of MediLink's B7-H3-targeting antibody-drug conjugate (ADC) YL201 and Amgen's DLL3- and CD3-targeting bispecific T-cell engager (BiTE) IMDELLTRA in extensive-stage small cell lung cancer (ES-SCLC). MediLink will provide the investigational drug YL201 for the combination study.
The open-label, multi-centre Phase Ib trial is aimed at assessing the safety, tolerability, pharmacokinetics and efficacy of this combination regimen in ES-SCLC patients.
Both YL201 and IMDELLTRA have shown potential in ES-SCLC.
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Merck reports positive Phase 3 results for WINREVAIR in pulmonary arterial hypertension
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid
Dizal completes enrolment in sunvozertinib vs. platinum doublet phase III study
UCB announces BIMZELX (bimekizumab-bkzx) three-year data at EULAR 2025
Sanofi expedites Beyfortus shipments to support early RSV season readiness
Mediar Therapeutics reports first IPF patient dosed in MTX-463 Phase 2 trial
Innovent's IBI363 granted second breakthrough therapy designation in China
bioMérieux launches rapid PCR test for equine respiratory diseases
BioNTech and Bristol Myers Squibb partner to co-develop bispecific antibody for solid tumours